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Abstract
Objectives:  To  determine  the  prevalence  of  increased  serum  ﬁbrinogen  levels  and  its  associa-
tion with  cardiometabolic  risk  factors  in  overweight  or  obese  children  and  adolescents.
Methods: Cross-sectional  study  with  138  children  and  adolescents  (overweight  or  obese)
followed at  a  reference  outpatient  clinic  of  the  public  health  care  network.  Fibrinogen  concen-
tration was  divided  into  quartiles,  and  values  above  or  equal  to  the  third  quartile  were
considered  high.  The  association  between  high  ﬁbrinogen  values  and  cardiometabolic  risk  fac-
tors was  assessed  using  Pearson’s  chi-squared  test  or  Fisher’s  exact  test,  as  necessary.  Logistic
regression  was  used  to  adjust  variables  predictive  of  ﬁbrinogen  levels.  Analyses  were  performed
using SPSS  version  22.0  and  SAS  software,  considering  a  conﬁdence  interval  of  95%.
Results: Serum  ﬁbrinogen  levels  were  elevated  in  28.3%  of  individuals,  showing  association
with the  presence  of  high  CRP  (p  =  0.003,  PR:  2.41,  95%  CI:  1.30--4.46)  and  the  presence  of  four
or more  risk  factors  (p  =  0.042;  PR:  1.78,  95%  CI:  1.00--3.17).  After  a  logistic  regression,  only
elevated  CRP  remained  associated  with  altered  ﬁbrinogen  levels  (p  =  0.024;  PR:  1.32;  95%  CI:
1.09--5.25).
 Please cite this article as: Azevedo WF, Cantalice AS, Gonzaga NC, Simões MO, Guimarães AL, de Carvalho DF, et al. Fibrinogen:
ardiometabolic risk marker in obese or overweight children and adolescents. J Pediatr (Rio J). 2015;91:464--70.
 Study conducted at Núcleo de Estudos em Pesquisas Epidemiológicas (NEPE), Centro de Obesidade Infantil (COI), Universidade Estadual
a Paraíba (UEPB), João Pessoa, PB, Brazil.
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Conclusions:  Increased  ﬁbrinogen  was  prevalent  in  the  study  population  and  was  associated
with ultrasensitive  C-reactive  protein  and  the  presence  of  four  or  more  cardiovascular  risk
factors; it  should  be  included  in  the  assessment  of  individuals  at  risk.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Fibrinogênio:  marcador  de  risco  cardiometabólico  em  crianc¸as e  adolescentes  obesos
ou  com  sobrepeso
Resumo
Objetivos:  Veriﬁcar  a  prevalência  de  níveis  séricos  elevados  de  ﬁbrinogênio  e  sua  associac¸ão
com os  fatores  de  risco  cardiometabólicos  em  crianc¸as  e  adolescentes  com  sobrepeso  ou  obesi-
dade.
Métodos: Estudo  transversal  com  138  crianc¸as  e  adolescentes  (obesos  ou  com  sobrepeso)  acom-
panhados  em  um  ambulatório  de  referência  da  rede  pública.  A  concentrac¸ão  do  ﬁbrinogênio  foi
distribuída  em  quartis,  sendo  considerada  elevada  quando  os  valores  eram  iguais  ou  superiores
ao terceiro  quartil.  A  associac¸ão  entre  o  valor  elevado  do  ﬁbrinogênio  com  os  fatores  de  risco
cardiometabólicos  foi  veriﬁcada  através  do  teste  qui-quadrado  de  Pearson  ou  teste  exato  de
Fisher, quando  necessário.  A  regressão  logística  foi  utilizada  para  ajuste  das  variáveis  predi-
toras do  nível  do  ﬁbrinogênio.  As  análises  foram  realizadas  no  SPSS  22.0  e  SAS,  considerando-se
o intervalo  de  conﬁanc¸a  de  95%.
Resultados:  Os  níveis  séricos  de  ﬁbrinogênio  estiveram  elevados  em  28.3%  dos  indivíduos,  apre-
sentando  associac¸ão  com  a  PCR  elevada  (RP:  2.41;  IC  95%:  1.30--4.46,  p  =  0.003)  e  com  a
presenc¸a de  quatro  ou  mais  fatores  de  risco  (RP:  1.78;  IC  95%:  1.00--3.17;  p  =  0.042).  Após
a regressão  logística,  apenas  o  PCR  elevado  continuou  associado  ao  ﬁbrinogênio  alterado  (RP:
1.32; IC  95%  1.09--5.25;  p  =  0.024).
Conclusões:  O  aumento  do  ﬁbrinogênio  foi  prevalente  na  populac¸ão  estudada  e  esteve  associado
à proteína  C  reativa  ultrassensível  e  ao  número  igual  ou  superior  a  quatro  de  fatores  de  risco
cardiovasculares,  devendo  ser  incluído  na  avaliac¸ão  de  indivíduos  sob  risco.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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eIntroduction
The  prevalence  of  excess  weight  has  increased  in  all  age
groups  in  Brazil,  similar  to  what  has  occurred  worldwide.1
Data  from  the  Family  Budget  Survey2 show  that  the  pro-
portion  of  obese  children  has  increased  four-fold  in  the
last  20  years  and  three-fold  in  adolescents  in  the  same
period,  ﬁndings  similar  to  those  observed  in  developed
countries.3,4
Obesity  represents  a  subclinical  inﬂammatory  condition
that  results  in  a  considerable  number  of  cardiometabolic  risk
factors.5 Stoopa  et  al.,6 when  assessing  the  inﬂammatory
and  prothrombotic  status  of  children  and  adolescents  with
obesity  or  normal  weight,  found  elevated  ﬁbrinogen  levels  at
an  age  as  young  as  6  years  in  the  obese  children,  regardless
of  pubertal  status.
Inﬂammation  in  atherogenesis  is  caused  by  the  synthe-
sis,  secretion,  and  storage  of  proinﬂammatory  cytokines
by  adipocytes,  producing  a  state  of  low-grade  inﬂamma-
tion  with  vascular  and  metabolic  complications7 that  leads
to  vascular  endothelial  dysfunction,  considered  to  be  the
8onset  of  the  atherogenic  process. Coagulation  factors,
such  as  ﬁbrinogen,  blood  ﬂow,  and  inﬂammatory  factors,
have  gained  importance  in  establishing  the  atherosclerotic
c
arocess  and  are  considered  important  risk  factors  for  car-
iovascular  disease.7,9
Fibrinogen,  an  acute  phase  protein,  is  part  of  the  group
f  inﬂammatory  biomarkers  produced  by  hepatocytes  and  is
onsidered  an  important  marker  to  monitor  the  atheroscle-
otic  inﬂammatory  process  evolution,10 as  it  acts  on  the
enesis  of  the  atherothrombotic  process  through  regulation
f  cell  adhesion  and  proliferation,  vasoconstriction  at  the
ite  of  endothelial  injury,  stimulation  of  platelet  aggrega-
ion,  and  blood  viscosity.7,8
Although  the  association  of  obesity  with  hyperﬁbrino-
enemia  has  been  reported  in  children,  the  association
f  ﬁbrinogen  with  cardiometabolic  risk  factors  is  not  yet
ell-established.11,12 The  search  for  biomarkers  for  early
dentiﬁcation  of  individuals  at  higher  risk  of  develop-
ng  atherosclerosis  and  the  knowledge  of  its  association
ith  other  cardiometabolic  risk  factors  is  critical  for  the
nderstanding  and  development  of  interventions  aimed  at
educing  morbidity  and  mortality  from  cardiovascular  dis-
ase.
Thus,  this  study  aimed  to  determine  the  prevalence  of
levated  serum  levels  of  ﬁbrinogen  and  its  association  with
ardiometabolic  risk  factors  in  overweight  or  obese  children
nd  adolescents.
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ethods
ross-sectional  study,  conducted  between  June  of  2011
nd  April  of  2012,  at  the  Centro  de  Obesidade  Infantil
Childhood  Obesity  Center  --  COI),  located  at  Instituto  de
aúde  Elpídeo  de  Almeida  (ISEA),  Campina  Grande-PB.  COI
s  a  referral  service  for  childhood  obesity  in  the  city  and
onsists  of  researchers  and  a  multidisciplinary  team  that
ncludes  doctors  (pediatrician  and  endocrinologist),  phar-
acists,  nutritionists,  psychologists,  nurses,  social  workers,
nd  physical  education  professionals.
When  the  research  began,  there  were  450  obese  or  over-
eight  children  and  adolescents  enrolled  at  COI.  The  study
ncluded  those  who  attended  COI  throughout  the  study
eriod,  comprising  a  convenience  sample  of  138  children
nd  adolescents.  Those  with  diseases  receiving  medication
hat  interfered  with  glucose  or  lipid  metabolism;  those  with
 diagnosis  of  genetic  syndrome;  and  those  who  achieved  a
utritional  status  of  normal  weight  were  excluded.  For  study
urposes,  the  calculation  of  the  sample  statistical  power
as  performed  retrospectively  in  order  to  allow  estimation
f  altered  ﬁbrinogen  prevalence  of  28.3%,  to  ensure  that
he  sample  size  allowed  attaining  the  proposed  objectives.
or  measures  of  association,  the  sample  showed  a  statistical
ower  of  85%  (ˇ  =  15%)  for  the  conﬁdence  level  of  95%.
The  anthropometric  variables  (weight,  height,  and  waist
ircumference)  were  veriﬁed  in  duplicate,  considering  the
ean  value  of  two  measurements,  according  to  the  recom-
endations  of  the  World  Health  Organization  (WHO).13
Nutritional  status  was  classiﬁed  according  to  body  mass
ndex  (BMI),  as  recommended  by  the  Centers  for  Disease
ontrol  and  Prevention  (CDC)  as  overweight  (BMI  ≥85th
ercentile  and  <95th  percentile),  obesity  (BMI  ≥95th  per-
entile  and  <97th  percentile),  and  severe  obesity  (BMI
97th  percentile).14 Waist  circumference  (WC)  was  consid-
red  increased  when  ≥the  90th  percentile,  according  to
he  International  Diabetes  Federation  (IDF).15 with  a maxi-
um  limit  of  88  cm  for  girls  and  102  cm  for  boys,  according
o  the  National  Cholesterol  Education  Program-Adult  Treat-
ent  Panel  III  (NCEP-ATPIII).16
Blood  pressure  was  measured  by  the  oscillometric
ethod  in  a  Tycos® (Welch  Allyn  Inc.,  NY,  USA)  device,
ccording  to  the  guidelines  established  in  the  VI  Brazilian
uidelines  on  Arterial  Hypertension.17
Total  cholesterol  (TC),  high-density  lipoprotein  choles-
erol  (HDL-C),  triglycerides  (TG),  and  glycemia  were
valuated  by  the  enzymatic  colorimetric  method  in
utomated  equipment  (BioSystems,  Model  310,  Applied
iosystems,  CA,  USA);  ﬁbrinogen  was  measured  by  the
oagulometric  method;  high-sensitivity  C-reactive  protein
hs-CRP)  and  insulin  by  chemiluminescence  in  IMMULITE
000  automated  equipment  (Siemens®,  Siemens  Healthcare,
rlangen,  Germany).  Low-density  lipoprotein  (LDL-c)  was
alculated  using  the  Friedewald  formula.18 Blood  collection
as  performed  after  a  12-h  fasting  period.
The  Homeostasis  Model  Assessment  of  Insulin  Resistance
HOMA-IR)  was  used  as  the  criterion  for  diagnosis  of  insulin
esistance  (IR),  classiﬁed  as  such  when  values  ≥2.5  were
ound.19
The  following  were  considered  cardiometabolic  risk
actors:  BMI  ≥97th  percentile,  WC  ≥90th  percentile  for  gen-
er,  age,  and  ethnicity,  with  a  maximum  limit  of  88  cm
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or  girls  and  102  cm  for  boys16; systolic  blood  pressure
SBP)  and/or  diastolic  blood  pressure  (DBP)  ≥90th  per-
entile  for  gender,  height,  and  age17;  TG  ≥130  mg/dL,  TC
170  mg/dL;  HDL-c  <  45  mg/dL;  LDL-c  ≥130  mg/dL;  fasting
lucose  ≥100  mg/dL;  insulin  ≥15  IU/mL;  HOMA-IR  ≥2.5;
nd  CRP  >  3  mg/L.20,21 Individuals  with  CRP  ≥10  mg/L  were
xcluded  from  the  analysis  of  this  variable,  as  in  these  cases,
t  is  recommended  to  rule  out  the  presence  of  an  acute
nﬂammatory  process.21
Fibrinogen  levels  were  divided  into  quartiles;  values  ≥the
5th  percentile  of  the  sample,  which  corresponds  to  3.4  g/L,
ere  considered  high,  as  there  is  no  established  cutoff  for
he  pediatric  population.22
The  project  was  approved  by  the  Research  Ethics  Com-
ittee  of  Universidade  Estadual  da  Paraíba  (UEPB)  (CAEE
-  0256.0.133.000-1)  and  was  performed  after  parents  or
uardians  signed  an  informed  consent,  authorizing  the  par-
icipation  of  their  children  in  the  study.
The  data  are  shown  as  percentage  and  median,  with  the
espective  interquartile  range  (IQ).  The  association  between
igh  ﬁbrinogen  values  (values  ≥the  75th  percentile)  with
ender,  age,  nutritional  status,  WC,  SBP,  DBP,  TG,  HDL-c,
DL-c,  TC,  blood  glucose,  insulin,  HOMA-IR,  and  hs-CRP  was
valuated  by  Pearson’s  chi-squared  test  or  Fisher’s  exact
est,  as  necessary,  with  prevalence  ratios  (PR)  and  their
espective  conﬁdence  intervals.
After  performing  the  Kolmogorov--Smirnov  test,  which
eriﬁed  a  non-parametric  distribution  of  the  ‘‘ﬁbrinogen’’
ariable,  the  Kruskal--Wallis  test  was  applied  to  test  the
ssociation  of  the  ﬁbrinogen  median  with  nutritional  sta-
us  (overweight,  obesity,  and  severe  obesity)  and  with  the
umber  of  cardiometabolic  risk  factors  (1  =  one  risk  factor;
 =  two  risk  factors;  3  =  three  risk  factors,  4  =  four  or  more
isk  factors).  Subsequently,  the  Mann--Whitney  test  was  used
o  evaluate  the  difference  of  these  measures  between  each
roup,  adjusted  to  ensure  that  the  ˛  error  did  not  exceed
he  value  of  0.05.
Multiple  logistic  regression  was  used  to  adjust  the  varia-
les,  whose  criteria  for  inclusion  was  the  association  with
he  dependent  variable  in  the  bivariate  analysis  with  a
-value  <  0.20.  The  variables  were  included  in  the  regres-
ion  analysis  using  the  ‘‘Enter’’  method,  according  to  the
ecreasing  value  of  the  PR.  The  Hosmer  and  Lemeshow  test
as  used  as  a  measure  of  goodness-of-ﬁt  of  the  logistic
egression  models,  in  which  a  p  ≥  0.05  indicates  that  the
odel  is  adjusted.
The  analyses  were  performed  using  the  SPSS  program,
ersion  22.0  (SPSS  Inc,  Chicago,  USA)  and  SAS  University
dition  (SAS  Institute  Inc.,  Cary,  NC,  USA),  considering  a
onﬁdence  interval  of  95%  (95%  CI).
esults
iological,  clinical,  and  laboratory  characteristics  of  the
38  assessed  subjects  are  described  in  Tables  1  and  2.  The
bserved  percentage  for  cardiometabolic  risk  factors  was
.8%  for  only  one  factor,  13.0%  for  two,  28.3%  for  three,  and
2.9%  for  four  or  more  factors.
Elevated  ﬁbrinogen  levels  were  present  in  28.3%  of  the
articipants,  and  were  more  common  in  children  than  in
dolescents  (p  =  0.038;  PR:  1.80;  95%  CI:  1.06--3.05);  those
Fibrinogen  in  obese  children  and  adolescents  467
Table  1  Frequency  distribution  of  the  biological  and  clinical  variables  according  to  ﬁbrinogen  levels  in  children  and  adolescents
with overweight  or  obesity.
Variables  Fibrinogen  (g/L)  PR  (95%  CI)  p
≥3.4  (n  =  39)  <3.4  (n  =  99)
n  (%)  n  (%)
Gender  Male  28  (34.1) 54  (65.9) 1.74  0.063a
Female  11  (19.6)  45  (80.4)  (0.95--3.20)
Age range  Childhood  13  (43.3)  17  (56.7)  1.80  0.038a
Adolescence  26  (24.1)  82  (75.9)  (1.06--3.05)
Nutritional  status  BMI  ≥  p  97  27  (31.0)  60  (69.0)  1.32  0.345a
BMI  <  p  97  12  (23.5)  39  (76.5)  (0.73--2.37)
WC WC  ≥  p  90  32  (30.2)  74  (69.8)  1.34  0.549b
WC<  p  90  7  (22.6)  24  (77.4)  (0.66--2.73)
SBP SBP  ≥  p  90  9  (36.0)  16  (64.0)  1.39  0.439b
SBP  <  p  90  29  (25.9)  83  (74.1)  (0.76--2.56)
DBP DBP  ≥  p  90  12  (27.9)  31  (72.1)  0.97  0.922a
DBP  <  p  90  27  (28.7)  67  (71.3)  (0.55--1.73)
CRF ≥4  26  (35.6)  47  (64.4)  1.78  0.042a
<4  13  (20.0)  52  (80.0)  (1.00--3.17)
WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRF, cardiometabolic risk factors.
a Descriptive level of probability of the chi-squared test.
b Descriptive level of probability of correction.
Table  2  Frequency  distribution  of  laboratory  variables  according  to  ﬁbrinogen  groups  in  children  and  adolescents  with  over-
weight or  obesity.
Variables  Fibrinogen  (g/L)  PR  (95%  CI)  p
≥3.4  (n  =  39)  <3.4  (n  =  99)
n  (%)  n  (%)
TG  Elevated  13  (21.7)  47  (78.3)  0.63  0.131a
Normal  26  (33.3)  52  (66.7)  (0.37--1.15)
TC Elevated  16  (29.6)  38  (70.4)  1.08  0.775a
Normal  23  (27.4)  61  (72.6)  (0.63--1.85)
LDL-c Elevated  9  (36.0)  16  (64.0)  1.32  0.532b
Normal  30  (27.3)  80  (72.7)  (0.72--2.42)
HDL-c Low  36  (29.5)  86  (70.5)  1.38  0.757c
Normal  3  (21.4)  11  (78.6)  (0.49--3.90)
Glycemia  Elevated  0  (0.0)  1  (100.0)  --  --
Normal 39  (28.5)  98  (71.5)  --
Insulin Elevated  13  (33.3)  26  (66.7)  1.27  0.406a
Normal  26  (26.3)  73  (73.7)  (0.73--  2.21)
IR Present  17  (34.7)  32  (65.3)  1.40  0.213a
Absent  22  (24.7)  67  (75.3)  (0.83--2.38)
CRP Elevated  21  (39.6)  32  (60.4)  2.41  0.003a
Normal  12  (16.4)  61  (83.6)  (1.30--4.46)
TG, triglycerides; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; IR,
insulin-resistance; CRP, C-reactive protein.
a Descriptive level of probability of the chi-squared test.
b Descriptive level of probability of correction.
c Descriptive level of probability of Fisher’s exact test.
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Table  3  Values  of  crude  and  adjusted  prevalence  ratio  (95%  CI)  of  ﬁbrinogen  alterations  in  children  and  adolescents  with
overweight or  obesity.
Parameter  Variables  Crude  PR  Adjusted  PR  Adjusted  p  (95%  CI)  Hosmer  and  Lemeshow
Fibrinogen  CRP  >  3  mg/L  2.41  1.32  0.024  (1.091--5.253)
0.648CRF ≥  4  1.78  1.11  0.545  (0.483--2.591)
Age range  (10--19  years)  1.80  0.78  0.263  (0.211--1.260)
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lCRP, C-reactive protein; CRF, cardiometabolic risk factors.
ith  four  or  more  cardiometabolic  risk  factors  (p  =  0.042;
R:  1.78;  95%  CI:  1.00--3.17),  and  in  those  with  high  CRP
evels  (p  =  0.003;  PR:  2.41;  95%  CI:  1.30--4.46).  The  latter
as  present  in  52.9%  of  the  participants.
There  was  no  statistically  signiﬁcant  difference  in  rela-
ion  to  ﬁbrinogen  median  with  nutritional  status  categories:
verweight  =  3.0  (IQ:  2.3--3.6);  obesity  =  2.5  (IQ:  2.1--3.2);
evere  obesity  =  2.6  (IQ:  2.2--3.5);  p  =  0.284.  In  the  relation
o  the  cardiometabolic  risk,  it  was  observed  that  the  ﬁbrino-
en  median  increased  as  the  number  of  risk  factors  increased
p  = 0.002).  This  difference  occurred  in  the  groups  with  two
nd  four  or  more  risk  factors  (p  =  0.003;  Fig.  1).
At  the  multiple  logistic  regression,  CRP  level  >  3  mg/L
as  independently  associated  with  high  ﬁbrinogen  levels
≥the  75th  percentile),  with  a  risk  of  1.32  (p  =  0.024;  95%  CI:
.09--5.25).  The  ﬁnal  model,  which  included  as  explanatory
ariables  CRP  levels  >3  mg/L,  the  number  of  risk  factors  ≥4,
nd  the  age  group  (10--18  years)  showed  a  good  ﬁt,  assessed
y  the  Hosmer  and  Lemeshow  test  (0.648;  Table  3).
iscussionn  the  present  study,  most  assessed  individuals  were  obese
nd  had  four  or  more  cardiometabolic  risk  factors.  It  was
lso  observed  that  high  level  of  ﬁbrinogen,  one  of  the  pro-
hrombotic  state  evaluation  factors,  was  present  in  more
Med. me dian; IQ.  interquartile range. 
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lhan  one  quarter  of  the  sample.  The  prothrombotic  state  is
onsidered  as  the  imbalance  between  procoagulant  and  pro-
brinolytic  factors,  characterized,  mainly  from  laboratory
nalysis,  by  increase  in  ﬁbrinogen  levels,  by  plasminogen
ctivation  inhibitor-1  (PAI-1),  and  by  activation  of  the  coag-
lation  pathways,  as  well  as  associated  with  endothelial
ysfunction.23
In  obese  individuals,  the  increase  in  ﬁbrinogen  levels  and
ther  coagulation  factors,  such  as  PAI-1  and  von  Willebrand
actor  (vWF-Ag),  has  been  associated  with  an  increase  in
ardiovascular  events.24 Some  studies8,22 have  found  signiﬁ-
antly  higher  ﬁbrinogen  levels  in  overweight  children,  when
ompared  with  levels  found  in  children  with  normal  weight.
The  high  levels  of  ﬁbrinogen  in  obese  children  may  be
xplained  by  the  increase  in  its  synthesis.  Although  there  is
o  report  of  its  production  by  adipose  tissue,  the  release  of
dipocytokines  into  the  portal  circulation  would  inﬂuence
he  production  of  ﬁbrinogen  and  other  coagulation  factors
n  the  liver.7
A  study  carried  out  with  313  obese  children  and  adoles-
ents  detected  a  lower  prevalence  of  increase  in  ﬁbrinogen
evels  (10.7%)24 when  compared  to  that  in  the  present  study
28.3%).  This  can  be  explained  because  the  abovementioned
tudy  used  a  cutoff  (4.0  g/L  to  4.5  g/L)  to  consider  ﬁbrin-
gen  levels  as  elevated,  which  was  higher  than  that  used
n  the  present  study  (3.4  g/L).  Such  comparisons  between
tudies  are  difﬁcult,  as  there  is  no  consensus  for  the  normal
alue  of  ﬁbrinogen  levels  in  childhood.25 Additionally,  the
ehavior  of  cardiovascular  risk  factors  may  vary  according
o  ethnicity.24
Fibrinogen  levels  found  in  current  studies  are  of  concern,
specially  because  they  are  elevated  both  in  prepubertal
nd  pubertal  obese  children.6 Although  the  process  of  fatty
treak  and  atheromatous  plaque  formation  have  been  iden-
iﬁed  pathologically,  mainly  in  adolescents,  the  signiﬁcant
ncrease  in  markers  such  as  ﬁbrinogen  and  PAI-1  in  obese
hildren  suggests  the  increase  in  cardiovascular  risk  in  this
ge  group,  which  may  cause  the  formation  of  atherosclerotic
laques  before  puberty  onset  in  young  obese  individuals.26
Regarding  the  assessed  cardiometabolic  risk  factors,  all
hildren  and  adolescents  had  at  least  one  risk  factor.  The
edian  of  ﬁbrinogen  serum  levels  was  associated  with  an
ncreased  number  of  risk  factors.  This  can  be  explained
y  the  potentiation  of  cardiometabolic  risk  due  to  the
ggregation  of  several  biomarkers  that  are  unfavorable  for
ardiovascular  health.22 This  ﬁnding  reinforces  the  impor-
ance  of  carrying  out  an  early  intervention  in  overweight  or
bese  children  and  adolescents,  especially  in  the  presence
f  four  or  more  risk  factors,  as  the  normalization  of  ﬁbrin-
gen  levels  has  been  reported  after  weight  loss,  changes  in
ifestyle,  and  practice  of  physical  exercise.5
ﬁ
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Studies  have  also  shown  the  association  of  some
cardiometabolic  risk  factors  with  elevated  ﬁbrinogen  lev-
els  from  childhood,  such  as  BMI,6,24 HOMA-IR,6,25 fasting
insulin,6,24,25 glycemia,26 triglycerides,  total  cholesterol,
LDL-c,  and  low  HDL-c.24
In  this  study,  ﬁbrinogen  was  associated  only  with  hs-
CRP  and  the  presence  of  four  or  more  cardiometabolic
risk  factors.  This  may  be  due  to  the  characteristics  of
the  sample,  which  includes  only  children  and  adolescents
with  overweight  and  obesity,  conditions  associated  with
a  proinﬂammatory  state,  unlike  other  abovementioned
studies.6,24,25 After  the  logistic  regression  was  performed,
the  value  of  hs-CRP  remained  a  predictor  of  high  ﬁbrinogen
levels  and  was  associated  with  a  1.3-fold  higher  chance  of
developing  this  condition.
In relation  to  the  lipid  proﬁle,  although  no  association
was  found  with  ﬁbrinogen,  the  highest  prevalence  of  total
cholesterol  and  LDL-C  was  observed  among  those  who  had
high  ﬁbrinogen  levels.  The  association  between  vascular
alterations  and  lipoproteins,  especially  those  of  low-density,
has  been  explained  as  originating  from  the  damage  induced
by  oxygen-free  radicals,  which  promote  the  destruction  of
endothelial  cells  by  oxidizing  these  lipoproteins,  trigger-
ing  a  cascade  of  alterations  including  hypercoagulability
and  decreased  ﬁbrinolysis,  signaled  by  increased  ﬁbrinogen
production.24
This  promotes  atherosclerosis  through  several  mecha-
nisms:  by  binding  to  endothelial  cell  receptors  (Intercellular
Adhesion  Molecule  1-ICAM1);  triggering  the  release  of
vasoactive  mediators,  smooth-muscle  cell  proliferation,  and
monocyte  chemotaxis  induction;  and  by  playing  a  role  in
foam  cell  formation  and  facilitating  the  transfer  of  choles-
terol  from  platelets  to  macrophages  and  monocytes.6
It  is  important  to  note  that  ﬁbrinogen  is  an  acute-
phase  inﬂammation  protein  with  procoagulant  activity  and,
together  with  hs-CRP,  has  been  used  to  predict  cardiovascu-
lar  disease  in  different  groups.  Both  seem  to  be  more  reliable
markers  than  interleukin-6  (IL-6),  which  has  a  short  half-
life.27 It  should  also  be  noted  that  inﬂammation  plays  a key
role  in  the  onset  and  promotion  of  atherosclerosis  and  can
lead  to  acute  coronary  syndrome  (ACS),  by  inducing  plaque
instability.23
This  study  has  some  limitations,  such  as  the  lack  of  a
cutoff  in  literature  for  normal  ﬁbrinogen  levels  in  children
and  adolescents,  making  it  difﬁcult  to  compare  studies;  the
scope  of  age  range,  as  there  are  peculiar  characteristics  in
the  different  groups,  such  as  pubertal  stage,  which  inter-
feres  with  the  metabolism  and  fat  deposition,  although  this
fact  has  not  been  observed  in  relation  to  ﬁbrinogen;  the  iso-
lated  use  of  ﬁbrinogen  as  a  marker  for  the  assessment  of  the
prothrombotic  state,  although  some  researchers  consider  it
a  more  reliable  marker  of  cardiovascular  disease  than  IL-627;
and  the  use  of  a  convenience  sample,  which  may  not  reﬂect
the  characteristics  of  the  overall  population.
It  is  worth  mentioning  that  these  limitations  do  not  dimin-
ish  the  importance  of  this  study,  as  it  innovates  by  assessing
the  ﬁbrinogen  behavior  in  relation  to  cardiometabolic  risk
factors  in  Brazilian  children  and  adolescents  with  excess
weight.  That  is  due  to  the  fact  that  studies  published  in
the  literature  on  this  topic  have  been  conducted  in  other
countries  and,  as  mentioned  previously,  this  ratio  can  vary
with  ethnicity.28
1469
Therefore,  the  ﬁndings  reinforce  the  concept  that  the
brinogen  and  hsCRP  are  potential  biomarkers  that  can  be
sed  in  obese  children,  even  in  those  without  associated
omplications,  for  the  screening  of  children  and  adolescents
t  risk  of  developing  cardiovascular  disease.  It  is  also  note-
orthy  that  longitudinal  studies  are  needed  to  elucidate  the
ole  of  these  biomarkers  in  the  genesis  of  atherosclerotic
isease  in  childhood.
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